scholarly journals Insulin resistance and impaired fat tolerance in men with coronary heart disease and ideal body weight

2004 ◽  
Vol 50 (5) ◽  
pp. 27-32
Author(s):  
I. V. Dvoryashina ◽  
N. T. Starkova ◽  
A. B. Antonov ◽  
Yu. Yu. Monogarova
Keyword(s):  
Insulin Resistance ◽  
Coronary Heart Disease ◽  
Body Weight ◽  
Heart Disease ◽  
Ideal Body Weight ◽  
Insulin Resistance Syndrome ◽  
Control Group ◽  
Blood Levels ◽  
Fatty Tissue ◽  
Ideal Body

Hormonal and metabolic disorders underlie the development of coronary heart disease (CHD). Insulin resistance, hyperinsulinemia, dyslipdemia and frequently obesity play a particular role in the pathogenesis of this disease. The purpose of this study was to characterize the basic parameters of the metabolic insulin resistance syndrome in males with CHD and an ideal body weight. A hundred and fifty-eight males were examined. They were divided into 3 groups: 1) patients with CHD and an ideal body weight; 2) those with CHD and obesity; and 3) males without CHD and obesity (a control group). The patients underwent athropometric studies; computed tomography was performed to determine the volume of abdominal fatty tissue; the blood levels of glucose, insulin, and lipids were measured. Dietary food load tests were used to study the functional activity of the lipid-transport system. Group 1 patients were found to have the major signs of the metabolic insulin-resistance syndrome: basal and stimulated hyperinsulinemia, dyslipidemia, the increased volume of visceral fatty tissue, and impaired fat tolerance.

Prevalences of Type 2 Diabetes, the Insulin Resistance Syndrome, and Coronary Heart Disease in an Elderly, Biethnic Population

Diabetes Care ◽  
1998 ◽  
Vol 21 (6) ◽  
pp. 959-966 ◽  
Author(s):  
R. D. Lindeman ◽  
L. J. Romero ◽  
R. Hundley ◽  
A. S. Allen ◽  
H. C. Liang ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Insulin Resistance Syndrome

scholarly journals Insulin Resistance Syndrome Predicts Coronary Heart Disease Events in Elderly Type 2 Diabetic Men

Diabetes Care ◽  
2001 ◽  
Vol 24 (9) ◽  
pp. 1629-1633 ◽  
Author(s):  
J. Kuusisto ◽  
P. Lempiainen ◽  
L. Mykkanen ◽  
M. Laakso
Keyword(s):  
Insulin Resistance ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Insulin Resistance Syndrome ◽  
Type 2 Diabetic

scholarly journals Strategy to calculate magnesium sulfate dose in obese patients: A randomized blind trial

2021 ◽  
Author(s):  
Sebastião E. Silva Filho ◽  
Omar S. Klinsky ◽  
Joaquim E. Vieira
Keyword(s):  
Body Weight ◽  
Laparoscopic Cholecystectomy ◽  
Magnesium Sulfate ◽  
Postoperative Period ◽  
Ideal Body Weight ◽  
Morphine Consumption ◽  
Control Group ◽  
Obese Patients ◽  
Pain Scores ◽  
Ideal Body

Abstract BACKGROUNDMagnesium sulfate has analgesic properties in the postoperative period. Among obese patients, there is a gap in the knowledge of its pharmacology related to the use of real, ideal, or corrected ideal body weight in calculating its dose. This trial compared postoperative analgesia using actual and corrected ideal body weight.METHODSSeventy-five obese patients scheduled to undergo laparoscopic cholecystectomy under general anesthesia were randomly assigned to three groups. Patients in the control group received no magnesium sulfate; patients in the other two groups received magnesium sulfate 40 mg·kg− 1 of actual body weight or corrected ideal body weight. A ten nonobese patients group helped us as a model of the expected blood magnesium concentration after magnesium sulfate administration in general population.RESULTSPatients from the groups receiving magnesium sulfate showed significant reduction in morphine consumption (p ≤ 0.001) and pain scores (p = 0.006) in the postoperative period compared to the control group. There was no significant difference in the consumption of morphine (p = 0.323) or pain scores (p = 0.082) between these groups. There was no difference in the total duration of neuromuscular block induced by cisatracurium among the three groups (p = 0.181) or in the blood magnesium concentrations throughout the study.CONCLUSIONSMagnesium sulfate decreased postoperative pain and morphine consumption without affecting cisatracurium recovery time in obese patients undergoing laparoscopic cholecystectomy. Analgesic profile was similar in groups receiving magnesium sulfate calculated through real or corrected ideal body weight.TRIAL REGISTRATIONclinicaltrials.gov NCT04003688. (Date of registration: June 24, 2019)

scholarly journals Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence

2015 ◽  
Vol 42 (11) ◽  
pp. 2092-2097 ◽  
Author(s):  
Laura Durcan ◽  
William A. Clarke ◽  
Laurence S. Magder ◽  
Michelle Petri
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Renal Failure ◽  
Body Weight ◽  
Disease Activity ◽  
Therapeutic Range ◽  
Lupus Erythematosus ◽  
Ideal Body Weight ◽  
Blood Levels ◽  
Systemic Lupus ◽  
Ideal Body

Objective.Hydroxychloroquine (HCQ) is used for its effect on systemic lupus erythematosus (SLE) disease activity and longterm benefits. This can be limited by adherence. One way to assess adherence is to measure blood levels. Conflicting data exist regarding blood levels and disease activity. There is disagreement about dosing; rheumatologists recommend weight-based dosing while some other specialists advocate height-based “ideal body weight” dosing.Methods.Patients were prescribed HCQ not exceeding 6.5 mg/kg (max 400 mg/day). In hemodialysis, the dose was 200 mg after each session, and in renal insufficiency it was 200 mg/day. Levels were measured at each visit with a therapeutic range of 500–2000 ng/ml. Patients were divided according to baseline blood level. To assess the effect of measurement and counseling on adherence, we compared the proportion of patients with a level of 500 ng/ml or higher based on the number of prior assessments.Results.The proportion of patients with HCQ levels in the therapeutic range differed significantly by age, sex, and Vitamin D level. There was a trend toward lower levels with renal failure. Blood levels were similar regardless of height and ideal body weight. Comparing those with undetectable, subtherapeutic, and therapeutic levels, disease activity decreased (SLE Disease Activity Index 2.92, 2.36, and 2.20, p = 0.04 for trend). At first, 56% were therapeutic, and by the third measurement this increased to 80% (p ≤ 0.0001).Conclusion.There was a trend toward higher disease activity with lower HCQ levels. Renal failure dosing led to suboptimum levels. We show that weight-based dosing (max 400 mg daily) is appropriate and that height does not appear to influence levels. Measurement, counseling, and repeated testing can increase adherence rates.

scholarly journals Insulin Resistance Syndrome Predicts the Risk of Coronary Heart Disease and Stroke in Healthy Middle-Aged Men

2000 ◽  
Vol 20 (2) ◽  
pp. 538-544 ◽  
Author(s):  
Marja Pyörälä ◽  
Heikki Miettinen ◽  
Pirjo Halonen ◽  
Markku Laakso ◽  
Kalevi Pyörälä
Keyword(s):  
Insulin Resistance ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Insulin Resistance Syndrome ◽  
Middle Aged

Clinical Status and Lipid Metabolism Disorder and Antioxidant Protection in Patients with Coronary Heart Disease Depending on the State of Intestinal Biocenosis

2016 ◽  
pp. 71-74
Author(s):  
Olha Busygina
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Lipid Metabolism ◽  
Clinical Status ◽  
Intervention Group ◽  
Control Group ◽  
Blood Levels ◽  
Lipid Metabolism Disorder ◽  
Diene Conjugate ◽  
Intestinal Dysbiosis

The aim of the research: comparative study of parameters of lipid metabolism, products of lipid peroxidation and levels of antioxidant enzymes in patients with coronary heart disease with intestinal normobiocenosis and intestinal dysbiosis (DB) 1st and 2nd degree. Materials and methods. The study involved 145 patients aged from 50 to 65 years, 29 (20%) of them were women. The control group (1st group) included 20 apparently healthy individuals with intestinal normobiocenosis. The comparison group (2nd group) consisted of 23 patients with coronary heart disease, postinfarct cardiosclerosis, chronic heart failure (CHF) the II functional class (FC) (NYHA), without signs of intestinal DB. The intervention group (3rd group) included 102 CHD patients with postinfarct cardiosclerosis, CHF the II FC and intestinal dysbiosis 1-st and 2-nd degree. Patients in all groups were comparable for age and sex. Results. The study revealed that the presence of intestinal DB in CHD patients with CHF the II FC was associated with greater 1.5 times the frequency of angina attacks, with a greater 1.4 times frequency reduction of physical activity, with a longer history of CHD and more common burdened by CHD heredity. Patients with CHD with intestinal DB occur in more profound lipid disorders than patients without any signs of impaired intestinal biocenosis. Conclusion. The presence of the initial stages of intestinal biocenosis disorders is associated with high levels of malondialdehyde in blood, diene conjugate, total cholesterol, cholesterol of low-density lipoproteins, atherogenic coefficient and significantly lower blood levels of superoxide dismutase and catalase in comparison with similar indicators in CHD patients with intestinal normobiocenosis.

scholarly journals Retinol Binding Protein-4 Is Associated with TNF-αand Not Insulin Resistance in Subjects with Type 2 Diabetes Mellitus and Coronary Heart Disease

2009 ◽  
Vol 26 (3) ◽  
pp. 135-140 ◽  
Author(s):  
Nasser M. Al-Daghri ◽  
Omar S. Al-Attas ◽  
Majed Alokail ◽  
Hossam M. Draz ◽  
Ahmed Bamakhramah ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Hypoglycemic Agents ◽  
Control Group ◽  
Diabetic Patients ◽  
Oral Hypoglycemic Agents ◽  
Low Carbohydrate Diet

We studied the association between RBP4 and various markers related to insulin resistance and diabetic complications as well as inflammatory markers in Saudi population suffering from type 2 diabetes and coronary heart disease. Patients with type 2 diabetes were divided into 3 groups according to the type of treatment and involvement of coronary artery disease. Serum RBP4, TNF-α, insulin, CRP, resistin, leptin and adiponectin were analysed in all samples. RBP4 levels increased significantly in the group of diabetic subjects treated with oral hypoglycemic agents and diabetic patients with coronary heart disease (30.2 ± 11.8; 33.4 ± 13.6 respectively), while there was no significant change in the other group for diabetic subjects on low-carbohydrate diet (25.1 ± 10.9) compared to control group (22.6 ± 9.5). RPB4 levels were positively correlated with TNF-α in the group of diabetic subjects on oral hypoglycemic agents and diabetic patients with coronary heart disease (r= 0.52,P< 0.05;r= 0.58,P< 0.05 respectively). No correlations were found between RBP4 levels and insulin resistance in all studied groups. Our findings suggest that serum RBP4 levels is associated with pro-inflammatory cytokine (TNF-α) and is not associated with insulin resistance among patients with type 2 diabetes and coronary heart disease.

Sign in / Sign up

Export Citation Format

Share Document